<DOC>
	<DOCNO>NCT00000770</DOCNO>
	<brief_summary>To assess safety toxicity zidovudine ( AZT ) /didanosine ( ddI ) versus AZT/ddI combine nevirapine HIV-infected patient , obtain preliminary anti-HIV activity data use immunologic virologic marker . Previous vitro study suggest HIV already develop resistance AZT ddI less able develop resistance nevirapine , non-nucleoside reverse transcriptase inhibitor . Thus , convergent combination therapy three drug HIV-infected patient may prove effective .</brief_summary>
	<brief_title>A Comparative Study Combination Zidovudine , Didanosine , Double-Blinded Nevirapine Versus Combination Zidovudine Didanosine</brief_title>
	<detailed_description>Previous vitro study suggest HIV already develop resistance AZT ddI less able develop resistance nevirapine , non-nucleoside reverse transcriptase inhibitor . Thus , convergent combination therapy three drug HIV-infected patient may prove effective . Patients randomize receive AZT/ddI plus either nevirapine placebo daily 48 week , possible extension least 12 week . At eight participate site , ACTG 808 809 conduct virologic pharmacokinetic substudies .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : PCP prophylaxis patient CD4 count &lt; 200 cells/mm3 prior history PCP . Allowed : Trimethoprim sulfamethoxazole dapsone , intravenous pentamidine , atovaquone , primaquineclindamycin trimetrexate acute PCP . Topical antifungal , clotrimazole , ketoconazole , fluconazole , amphotericin B treatment mucosal esophageal candidiasis . Prophylaxis therapy opportunistic infection , indicate , medication itraconazole , isoniazid , pyrazinamide , clofazimine , clarithromycin , azithromycin , ethambutol , amikacin , ciprofloxacin , ofloxacin , pyrimethamine , sulfadiazine , clindamycin . Maintenance therapy opportunistic infection long patient stable dosage regimen 1 month prior study entry . Ganciclovir CMV retinitis gastrointestinal disease long patient stable dose least 1 month prior study entry grade 3 4 neutropenia dependence GCSF . Acyclovir ( &lt; = 1000 mg/day ) maintenance herpes simplex virus infection . Erythropoietin GCSF clinically indicate . Antibiotics bacterial infection unless specifically exclude . Rifampin rifabutin . Symptomatic treatment antipyretic , analgesic , antiemetic . Concurrent Treatment : Allowed : Local radiation therapy . Prior Medication : Required : At least 6 month prior cumulative nucleoside therapy AZT , ddI , ddC , give monotherapy combination . Patients must : Prior current documentation HIV seropositivity ELISA confirm Western blot , positive HIV antigen , positive HIV culture , second antibody test method ELISA . CD4 count &lt; = 350 cells/mm3 . Prior cumulative nucleoside therapy &gt; = 6 month . Consent parent guardian le 18 year age . Exclusion Criteria Concurrent Medication : Excluded : Antiretroviral therapy study medication . Systemic corticosteroid give consecutively &gt; 21 day . Induction maintenance foscarnet . Systemic cytotoxic chemotherapy malignancy . Erythromycin . Coumadin/warfarin . Phenytoin phenobarbital . Amoxicillin/clavulanate acid ( Augmentin ) ticarcillin/clavulanate acid ( Timentin ) . Patients follow prior condition exclude : History pancreatitis . History intolerance 500 600 mg/day AZT 400 mg/day ddI tablet 500 mg/day ddI sachet . History grade 2 bad peripheral neuropathy . Prior Medication : Excluded time : Prior nonnucleoside reverse transcriptase inhibitor ( NVP ; L697,611 ; TIBO ; atevirdine ) . Excluded within 14 day prior study entry : Acute treatment serious infection opportunistic infection . Biologic response modifier interferon IL2 . Erythromycin . Coumadin/warfarin . Phenytoin phenobarbital . Ticarcillin/clavulanate acid ( Timentin ) amoxicillin/clavulanate acid ( Augmentin ) .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
</DOC>